Opinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention

Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options.

The implications for U.S. public health are vast.